(PDF) P1.13-15 Detection of EGFR Mutations in cfDNA and

P1.13-15 Detection of EGFR Mutations in cfDNA and Development of Resistance

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.872

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

P1.13-23 TP53 Mutations as Mechanisms of Primary and Acquired Resistance to Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

Clinical Cancer Research

Cancer Research

English

P1.13-27 a Randomized Study of Concurrent vs Sequential Alternating EGFR-TKIs and Chemotherapy for Advanced NSCLC With EGFR Mutations

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.13-13 Potent Anti-Tumor Effect of Ganetespib in Acquired EGFR-TKI Resistance NSCLC Cells

Journal of Thoracic Oncology

Respiratory Medicine

English

Patient With Three EGFR Mutations – Gradual Development of Resistance to Previous Targeted Treatment

Klinicka Onkologie

English

P1.13-11 PRO-CTCAE Toxicities in Advanced NSCLC Patients With EGFR Mutations: A Real World Assessment

Journal of Thoracic Oncology

Respiratory Medicine

English

Allosterically Targeting EGFR Drug-Resistance Gatekeeper Mutations

Journal of Thoracic Disease

Respiratory Medicine

English

P2.13-15 Short-Term Responders of NSCLC to EGFR-TKIs Display High Prevalence of TP53 Mutations and Primary Resistance Mechanisms

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.13-21 Clinical Efficacy and Safety of Apatinib Combined With EGFR - TKIs in Advanced Non-Small Cell Lung Cancer With EGFR - TKIs Resistance

Journal of Thoracic Oncology

Respiratory Medicine

English